European Medical Solutions (STU:AS00) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AS00 European Medical Solutions STU:AS00
43 GF Score
Price €3.98
GF Value €8.16
! 2 Warning Signs
View Full Analysis

What is European Medical Solutions Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:AS00
43GF Score
European Medical Solutions STU:AS00
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is European Medical Solutions (STU:AS00) Overvalued in 2026?

Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued. The current stock price of €3.98 is trading 51.2% below its estimated GF Value™ of €8.16.

Key valuation signals for STU:AS00:

  • Dividends Received:
  • GF Value™: €8.16 vs. price of €3.98 (51.2% below fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


European Medical Solutions Business Description

Other Exchanges ALEMS:Belgium
Address 7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
43GF Score

Get the complete analysis for STU:AS00

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.98
Price
€8.16
GF Value